Adding years to life costs!
作者信息
Pathak Rima Sanjay, Tibdewal Anil, Agarwal Jai Prakash
机构信息
Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
出版信息
J Thorac Dis. 2022 Jul;14(7):2447-2450. doi: 10.21037/jtd-2022-07.
Abstract
摘要
相似文献
1
Adding years to life costs!延长寿命是有代价的！
J Thorac Dis. 2022 Jul;14(7):2447-2450. doi: 10.21037/jtd-2022-07.
2
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.在挪威儿童疫苗接种计划中添加7价肺炎球菌结合疫苗（PCV - 7）的成本效益。
Vaccine. 2006 Jul 17;24(29-30):5690-9. doi: 10.1016/j.vaccine.2006.04.042. Epub 2006 May 5.
3
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.德国类风湿关节炎序贯使用包括来氟米特在内的改善病情抗风湿药的成本效益和成本效用建模：II. 来氟米特对效率的贡献
Pharmacoeconomics. 2005;23(4):395-420. doi: 10.2165/00019053-200523040-00008.
4
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.阿利吉仑在2型糖尿病、高血压和蛋白尿中的成本效益
J Am Soc Nephrol. 2009 Oct;20(10):2205-13. doi: 10.1681/ASN.2008111144. Epub 2009 Sep 17.
6
Adding access blood flow surveillance to clinical monitoring reduces thrombosis rates and costs, and improves fistula patency in the short term: a controlled cohort study.在临床监测中增加通路血流量监测可降低血栓形成率和成本，并在短期内提高内瘘通畅率：一项对照队列研究。
Nephrol Dial Transplant. 2008 Nov;23(11):3578-84. doi: 10.1093/ndt/gfn275. Epub 2008 May 29.
7
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.阿尔茨海默病干预措施成本效用分析中的家庭和照护者溢出效应。
Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3.
8
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
9
Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States.在美国，作为癫痫辅助治疗药物，左乙拉西坦起始治疗前后的医疗资源利用和成本。
Epilepsy Behav. 2019 Oct;99:106331. doi: 10.1016/j.yebeh.2019.05.027. Epub 2019 Aug 6.
10
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.比索洛尔治疗瑞典慢性充血性心力衰竭的成本效益：使用心脏不全比索洛尔研究II试验数据进行的分析
Pharmacoeconomics. 2001;19(9):901-16. doi: 10.2165/00019053-200119090-00002.
本文引用的文献
1
Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer.转移性非小细胞肺癌立体定向体部放射治疗的趋势与成本
J Thorac Dis. 2022 Jul;14(7):2579-2590. doi: 10.21037/jtd-21-1835.
2
Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress.晚期非小细胞肺癌的免疫治疗：十年进展。
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-23. doi: 10.1200/EDBK_321483.
3
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.立体定向体部放疗后帕博利珠单抗与单纯帕博利珠单抗治疗晚期非小细胞肺癌患者肿瘤反应的效果：PEMBRO-RT 2期随机临床试验结果
JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.
4
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.寡转移非小细胞肺癌患者的局部巩固治疗与维持治疗或观察：多机构、Ⅱ期、随机研究的长期结果。
J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.
5
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.局限性转移性非小细胞肺癌的巩固性放疗：一项 2 期随机临床试验。
JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501.
6
Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates.慢性阻塞性肺疾病（COPD）综合病例管理项目对住院时间和再入院率的影响。
Int J Chron Obstruct Pulmon Dis. 2017 Mar 21;12:961-971. doi: 10.2147/COPD.S124385. eCollection 2017.
7
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.一线全身治疗后无进展的寡转移性非小细胞肺癌患者的局部巩固治疗与维持治疗或观察比较：一项多中心、随机、对照、2期研究
Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.
8
Can automation in radiotherapy reduce costs?
Acta Oncol. 2015;54(9):1282-8. doi: 10.3109/0284186X.2015.1073353. Epub 2015 Sep 23.
9
Preoperative staging of lung cancer with combined PET-CT.采用PET-CT联合检查对肺癌进行术前分期
N Engl J Med. 2009 Jul 2;361(1):32-9. doi: 10.1056/NEJMoa0900043.
10
Stereotactic body radiation therapy for oligometastases.寡转移瘤的立体定向体部放射治疗
Expert Rev Anticancer Ther. 2009 May;9(5):621-35. doi: 10.1586/era.09.15.
Zotero 插件